(14 days)
The Sprinter Legend RX and OTW 1.25mm Balloon Dilatation Catheter is indicated as a pre-dilatation catheter for enlarging coronary luminal diameters during PCI procedures.
The Medtronic Sprinter Legend 1.25mm RX and OTW are balloon dilatation catheters designed to perform Percutaneous Transluminal Coronary Angioplasty (PTCA).
Sprinter Legend 1.25mm RX
The device consists of a semicompliant balloon mounted on a Rapid Exchange delivery catheter. The Sprinter Legend 1.25mm RX device has an effective length of 142cm. It will be available in a single balloon diameter of 1.25mm and in balloon lengths from 6mm to 20mm.
Sprinter Legend 1.25mm OTW
The device consists of a semicompliant balloon mounted on an Over-the-Wire delivery catheter. The Sprinter Legend 1.25mm OTW device has an effective length of 152cm. Similar to Sprinter Legend 1.25mm RX, Sprinter Legend 1.25mm OTW will also be available in a 1.25mm balloon diameter and with balloon lengths from 6mm to 20mm.
This document describes the Sprinter Legend 1.25mm RX and OTW Balloon Dilatation Catheters for percutaneous transluminal coronary angioplasty (PTCA) procedures. It includes information on device description, indications for use, and a summary of a clinical study.
Here's an analysis of the provided text in relation to your questions:
Device: Sprinter Legend 1.25mm RX and OTW Balloon Dilatation Catheters
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for this device are derived from its "Indications For Use" and the "Primary Endpoint" of the clinical study, which focuses on procedural success, device success, and lesion success. The reported device performance metrics are directly from the study results.
| Acceptance Criteria (from Indications for Use & Study Primary Endpoint) | Reported Device Performance (from Clinical Study Results) |
|---|---|
| Device successfully used as a pre-dilatation catheter for enlarging coronary luminal diameters during PCI procedures. This is broken down into the following operational definitions: | Confirmed by: |
| Procedural Success: | 100.0% (51/51) |
| - Delivery of the balloon catheter to the target lesion and dilatation of the lesion using the study device. | |
| - No evidence of arterial perforation, flow limiting dissection, reduction in TIMI flow from baseline TIMI, or clinically significant arrhythmias following pre-dilatation step with the study device. | |
| - TIMI 3 flow post-dilatation at the conclusion of the PCI procedure. | |
| Device Success: | 100.0% (51/51) |
| - Delivery of the balloon catheter to the target lesion and dilatation of the lesion using the study device. | |
| - No evidence of arterial perforation, flow limiting dissection, reduction in TIMI flow from baseline TIMI, or clinically significant arrhythmias following pre-dilatation step with the study device. | |
| Lesion Success: | 100.0% (54/54) |
| - Delivery of the balloon catheter to the target lesion and dilatation of the lesion using any PCI method. | |
| Acceptably low rates of adverse events (as demonstrated by secondary endpoints). | Achieved with generally low rates, e.g., MACE 2.0%. |
| Successful assistance of subsequent PCI to enlarge coronary luminal diameters. | MLD pre-procedure of 0.623mm to 2.173mm post-procedure. |
| Resulting TIMI 3 coronary blood flow post-procedure. | 100% (54/54) of lesions. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size: 51 patients (54 lesions)
- Data Provenance: Prospective, multi-center, single-arm open-label study conducted at two (2) study sites in the United States. Clinical follow-up was conducted post-procedure until discharge.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
The document does not explicitly state the number of experts or their specific qualifications (e.g., "radiologist with 10 years of experience") used to establish ground truth. However, it mentions "angiographic core lab data" being used, which implies review by qualified personnel specializing in angiographic analysis.
4. Adjudication Method for the Test Set
The document does not explicitly state an adjudication method (e.g., 2+1, 3+1). It mentions "angiographic core lab data and if missing, site reported data" were used, which implies a hierarchical approach where core lab assessment is primary.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, and if so, what was the effect size of how much human readers improve with AI vs without AI assistance
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This document describes a clinical study for a physical medical device (balloon dilatation catheter), not an AI-assisted diagnostic tool. Therefore, there is no mention of human readers or AI assistance.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
No, a standalone (algorithm only) performance study was not done. This is a physical medical device.
7. The Type of Ground Truth Used
The ground truth was established through a combination of:
- Clinical outcomes: Directly observed procedural outcomes (e.g., successful delivery, absence of complications like arterial perforation or flow-limiting dissection, TIMI flow), device performance, and patient safety events (MACE, death, MI, etc.).
- Angiographic core lab data: For assessing aspects like TIMI flow and changes in Minimum Luminal Diameter (MLD).
- Site-reported data: Used to supplement angiographic core lab data when missing, particularly for TIMI and Perforation.
8. The Sample Size for the Training Set
This document describes a clinical study for a physical medical device; it does not mention a training set in the context of machine learning or AI. The study itself serves to demonstrate the safety and effectiveness of the device.
9. How the Ground Truth for the Training Set Was Established
As there is no mention of a training set (in the context of AI/machine learning) for this physical medical device, this question is not applicable to the provided text.
{0}------------------------------------------------
·
510(k) Summary
| Date Prepared: | October 21, 2010 | OCT 2 2 2010 |
|---|---|---|
| Applicant: | Medtronic IrelandParkmore Business Park WestGalwayIreland | |
| Primary Correspondent: | John-Paul HughesRegulatory Affairs SpecialistMedtronic IrelandParkmore Business Park WestGalwayIrelandPhone: (011-353-91) 708579Fax: (011-353-91) 708672Email: john-paul.hughes@medtronic.com | |
| Alternate Correspondent: | Gerardine FinnMedtronic Inc.Medtronic Vascular3576 Unocal PlaceSanta RosaCalifornia 95403USAPhone: (707) 566 1548Fax: (707) 566 1549Email: gerardine.finn@medtronic.com | |
| Proprietary Name: | - Sprinter Legend 1.25mm Rapid Exchange BalloonDilatation Catheter- Sprinter Legend 1.25mm Over-the-Wire Balloon DilatationCatheter |
.
・
1
Medtronic Ireland
Meditorie Tieland
Sprinter Legend 1.25mm RX & Sprinter Legend 1.25mm OTW Balloon Dilatation Catheters
510(k) K103095
{1}------------------------------------------------
| CONFIDENTIALMay not be reproduced without written permission from Medtronic Ireland | |
|---|---|
| Common Name: | Sprinter Legend 1.25mm RX and Sprinter Legend 1.25mm OTW |
| Device Classification Name: | Cardiovascular DevicesClass II, 21 CFR Part 814 |
| Product Code: | 74 LOX |
| Device Description: | The Medtronic Sprinter Legend 1.25mm RX and OTW are balloondilatation catheters designed to perform Percutaneous TransluminalCoronary Angioplasty (PTCA).Sprinter Legend 1.25mm RXThe device consists of a semicompliant balloon mounted on aRapid Exchange delivery catheter. The Sprinter Legend 1.25mmRX device has an effective length of 142cm. It will be available ina single balloon diameter of 1.25mm and in balloon lengths from6mm to 20mm.Sprinter Legend 1.25mm OTWThe device consists of a semicompliant balloon mounted on anOver-the-Wire delivery catheter. The Sprinter Legend 1.25mmOTW device has an effective length of 152cm. Similar to SprinterLegend 1.25mm RX, Sprinter Legend 1.25mm OTW will also beavailable in a 1.25mm balloon diameter and with balloon lengthsfrom 6mm to 20mm. |
| Indications For Use: | The Sprinter Legend RX and OTW 1.25mm Balloon DilatationCatheters are indicated as pre-dilatation catheters for enlargingcoronary luminal diameters during PCI procedures. |
| Substantially Equivalent Devices: | The Sprinter Legend 1.25mm RX and OTW Balloon DilatationCatheters use similar technology, materials and method ofoperation to the approved predicates Sprinter Legend RX device(1.5-4.0mm) (P790017/S096) and Sprinter OTW BalloonDilatation Catheter (P790017/S081). The indications for use forthese devices are similar to those of Sprinter Legend RX (1.5-4.0mm) and the Sprinter OTW devices. The properties of theSprinter Legend 1.25mm RX and Sprinter Legend 1.25mm OTWdevices to treat disease are identical to previously approved PTCAballoon dilatation catheters outlined above. |
:
י
{2}------------------------------------------------
Summary of Technological The Medtronic Sprinter Legend 1.25mm RX and OTW devices Characteristics: consist of a balloon at the distal end of the catheter, which can be inflated and deflated by a coaxial lumen, to a defined diameter at a specific pressure. This means that the inner shaft resides inside the distal outer shaft, leaving an annular space between the two for pressurized fluid to flow. For the OTW product the proximal end of the catheter has a luer for attachment to an inflation device. This bifurcated luer has two legs, one to control inflation and deflation of the catheter and one to allow insertion of a guidewire. The proximal section of the RX catheter is a single lumen stainless hypotube with a single luer port for attachment to an inflation device to control inflation and deflation of the catheter. Both catheters provide a lumen which enables the use of a guidewire to position the catheter. A radiopaque balloon marker, which facilitates imaging under fluoroscopy, enables accurate placement. Shaft markers for brachial and femoral techniques are in place. Summary of Studies: The following device integrity testing was completed using Sprinter Legend 1.25mm RX and or OTW devices: Catheter Dimensiona! Measurements & Profile . . Catheter Tensile Strength Radiopacity . Coating Testing . Balloon Compliance . System Pressure Capability . System Fatigue . Balloon Inflation and Deflation, Performance and Balloon . Preparation Interaction with Accessories . Wire Lumen Crush . Kissing Balloon Technique . Flexibility & Kink Test . Dye Flow through a Guide Catheter . Packaging Integrity Testing . The Medtronic Sprinter Legend 1.25mm RX and OTW Balloon Dilatation Catheters met all specified design and performance requirements. Summary of Clinical Data: Overview of Clinical Study Results of The Sprinter® Legend 1.25mm Trial Clinical data was required for the Sprinter Legend 1.25mm balloon diameter size to ensure that the technological characteristics of the small diameter balloon did not affect safety or effectiveness.
Medtronic Ireland Mouronio Kalano
Sprinter Legend 1.25mm RX & Sprinter Legend 1.25mm OTW Balloon Dilatation Catheters 510(k) K103095
{3}------------------------------------------------
Study Purpose:
To examine acute outcomes when the Sprinter Legend 1.25 mm OTW balloon catheter is used as a pre-dilatation catheter for enlarging coronary luminal diameters during PCI procedures with subsequent use, in most cases, of another PTCA catheter to complete the dilatation.
Design:
This was a prospective, multi-center, single arm open label study that evaluated acute outcomes when the Sprinter Legend 1.25 mm balloon catheter was used as a predilatation catheter for enlarging coronary luminal diameters during percutaneous coronary intervention (PCI) procedures.
Eligibility was based upon the assessment of the lesion's stenosis being ≥70% and included chronic total occlusions (CTOs). The primary endpoint in this study was the Procedural Success consisting of the following:
- · Delivery of the balloon catheter to the target lesion and dilatation of the lesion using the study device.
- · No evidence of arterial perforation, flow limiting dissection, reduction in TIMI flow from baseline TIMI or clinically significant arrhythmias following pre-dilatation step with the . study device.
- · TIMI 3 flow post-dilatation at the conclusion of the PCI procedure.
The secondary endpoints were Device success. Lesion success, Inhospital
MACE, Target Lesion Failure (TLF), Thrombosis, Dissection or perforation.
Balloon Rupture and Arrhythmias.
Device success consists of the following:
· Delivery of the balloon catheter to the target lesion and dilatation of the lesion using the study device
· No evidence of arterial perforation, flow limiting dissection, reduction in TIMI flow from baseline TIMI or clinically significant arrhythmias following predilatation step with the study device.
Lesion Success consists of the following:
• Delivery of the balloon catheter to the target lesion and dilatation of the lesion using any PCI method
A total of 51 patients were enrolled in this study at Two (2) study
{4}------------------------------------------------
sites in the United States. Clinical follow-up was conducted postprocedure until discharge.
Demographics:
Baseline demographic parameters for the enrolled population show that the mean age was 67.3 years and 90.2% (46/51) of the subjects were male. Additionally, 96.1% (49/51) subjects had hyperlipidemia and 96.1% (49/51) had hypertension.
Results:
The primary and secondary endpoint results are presented in Table l and 2 below. The combined data collected for the primary endpoint indicates that the procedural success was 100.0% (51/51) for this trial. The rate of device success was 100% (51/51) and that of lesion success was also 100% (54/54).
| Table 1: Effectiveness Measures | |||||
|---|---|---|---|---|---|
| -- | -- | -- | -- | -- | --------------------------------- |
| Primary Endpoint | Sprinter Legend 1.25mm(N=51 Subjects)(N=54 Lesions) |
|---|---|
| Procedure Success | 100.0% (51/51) |
| Device Success | 100.0% (51/51) |
| Lesion Success * | 100.0% (54/54) |
- Percentage is based on number of lesions with available data. Percentage is based on available angiographic core lab data and if missing, site reported data of post Sprinter Legend TIMI and Perforation are applied.
Table 2: Principal Safety and Effectiveness Results
| Secondary Endpoint | Sprinter Legend(N=51 Subjects)(N=54 Lesions) |
|---|---|
| Major Adverse Cardiac Event (MACE) | 2.0% (1/51) |
| Death | 0.0% (0/51) |
| Cardiac Death | 0.0% (0/51) |
| Target Vessel MI (TVMI, Medtronic Historic Definition) | 2.0% (1/51) |
| TVMI (ARC Definition) | 15.7% (8/51) |
| Emergent CABG | 0.0% (0/51) |
| Clinically Driven Target Lesion Revascularization (TLR) | 0.0% (0/51) |
| Dissection | 0.0% (0/51) |
| Flow Limiting Dissection | 0.0% (0/51) |
| Clinically Driven Target Vessel Revascularization (TVR) | 0.0% (0/51) |
| Perforation | 0.0% (0/51) |
| Clinical/Angiographic | 0.0% (0/51) |
| Thrombus | 0.0% (0/51) |
Medtronic Ireland
Sprinter Legend 1.25mm RX & Sprinter Legend 1.25mm OTW Balloon Dilatation Catheters 510(k) K103095
{5}------------------------------------------------
| Arrhythmias | 0.0% (0/51) |
|---|---|
| Target Lesion Failure (TLF) | 2.0% (1/51) |
| Target Vessel Failure (TVF) | 2.0% (1/51) |
| Stent Thrombosis (ARC Definite/Probable)1 | 0.0% (0/44) |
| Definite | 0.0% (0/44) |
| Probable | 0.0% (0/44) |
| Effectiveness Measures | |
| Procedure Success | 100.0% (51/51) |
| Device Success | 100.0% (51/51) |
| Lesion Success2 | 100.0% (54/54) |
Percentage is based on number of subjects with available data. except:
1 For subjects receiving stents
2 Percentage is based on number of lesions with available data
Conclusion:
The Sprinter® Legend 1.25 mm catheter trial met its primary endpoint of procedural success as well as the endpoints of lesion and device success and demonstrated acceptably low rates of adverse events.
Also, as evidenced by the angiographic core lab, 100% (54/54) of lesions had a resulting TIMI 3 coronary blood flow post-procedure further supporting the efficacy profile of this pre-dilatation catheter. The Sprinter Legend 1.25mm balloon successfully assisted subsequent percutaneous coronary interventions to enlarge coronary luminal diameters from a MLD preprocedure of 0.623mm to 2.173mm post-procedure.
In conclusion, the safety and efficacy data presented in this report illustrate the Sprinter Legend 1.25mm balloon may be used to successfully enlarge coronary luminal diameters during PCI procedures as a pre-dilatation balloon catheter.
{6}------------------------------------------------
| Biocompatibility Information: | The testing which supports the biocompatibility of the MedtronicSprinter Legend 1.25mm RX and OTW Balloon DilatationCatheter product family is consistent with International StandardISO10993-1:2009 "Biological Evaluation of Medical devices- Part1: Evaluation and Testing."When classified according to this standard, the catheter and dilatorincluded in the Medtronic Sprinter Legend 1.25mm RX and OTWBalloon Dilatation Catheter product family are categorized asexternal communicating devices with limited exposure i.e. whosecontact with circulating blood is ≤ 24 hours.The following Biocompatibility tests were performed:Cytotoxicity Using ISO Elution Method ASTM Hemolysis Study Material Mediated Pyrogen ISO Maximization Sensitization Study ISO Intracutaneous Study ISO Systemic Toxicity Study C3a and SC5b-9 Complement Activation Assay Study Physicochemical Tests ASTM Partial Thromboplastin Time Study (PTT) In Vivo Thromboresistance Study in the Dog, Jugular Vein The biocompatibility evaluation completed verifies that theMedtronic Sprinter Legend 1.25mm RX and OTW BalloonDilatation Catheters are biocompatible. |
|---|---|
| Sterilization Validation: | The Medtronic Sprinter Legend 1.25mm RX and OTW BalloonDilatation Catheters will be sterilized using a validated EthyleneOxide (EtO) sterilization process. |
| Conclusion: | Through the data and information presented, Medtronic Irelandconsiders the Medtronic Sprinter Legend 1.25mm RX and OTWBalloon Dilatation Catheters to be substantially equivalent to thepredicate devices. |
·
.
・
{7}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/7/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines forming its body and wing. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Medtronic Ireland c/o Ms. Gerardine Finn Vice President, Regulatory Affairs Medtronic, Inc. 3576 Unocal Place Santa Rosa, CA 95403
OCT 2 2 2010
Re: K103095
Trade/Device Name: Sprinter Legend 1.25mm Rapid Exchange Balloon Dilatation Catheter Sprinter Legend 1.25mm Over-the-Wire Balloon Dilatation Catheter Regulation Number: 21 CFR 870.5100 Regulation Name: PTCA Catheters Regulatory Class: Class II (two) Product Code: LOX Dated: Not Dated Received: October 8, 2010
Dear Ms. Finn:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{8}------------------------------------------------
Page 2 - Ms. Gerardine Finn
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{9}------------------------------------------------
CONFIDENTIAL May not be reproduced without written permission from Medtronic Ireland
.
Indication for Use
| 510(k) Number (if known): | K103095 | OCT 2 2 2010 |
|---|---|---|
| Device Name: | Medtronic Sprinter Legend 1.25mm RX and Sprinter Legend1.25mm OTW Balloon Dilatation Catheters | |
| Indications for Use: | The Sprinter Legend RX and OTW 1.25mm BalloonDilatation Catheter is indicated as a pre-dilatation catheterfor enlarging coronary luminal diameters during PCIprocedures. |
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Medtronic Ireland Sprinter Legend 1.25mm RX & Sprinter Legend 1.25mm OTW Balloon Dilatation Catheters 510(k) K103095
§ 870.5100 Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter.
(a)
Standard PTCA Catheter —(1)Identification. A PTCA catheter is a device that operates on the principle of hydraulic pressurization applied through an inflatable balloon attached to the distal end. A PTCA balloon catheter has a single or double lumen shaft. The catheter features a balloon of appropriate compliance for the clinical application, constructed from a polymer. The balloon is designed to uniformly expand to a specified diameter and length at a specific pressure as labeled, with well characterized rates of inflation and deflation and a defined burst pressure. The device generally features a type of radiographic marker to facilitate fluoroscopic visualization of the balloon during use. A PTCA catheter is intended for balloon dilatation of a hemodynamically significant coronary artery or bypass graft stenosis in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion. A PTCA catheter may also be intended for the treatment of acute myocardial infarction; treatment of in-stent restenosis (ISR) and/or post-deployment stent expansion.(2)
Classification. Class II (special controls). The special control for this device is “Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters.” See § 870.1(e) for the availability of this guidance document.(b)
Cutting/scoring PTCA Catheter —(1)Identification. A cutting/scoring PTCA catheter is a balloon-tipped catheter with cutting/scoring elements attached, which is used in those circumstances where a high pressure balloon resistant lesion is encountered. A cutting/scoring PTCA catheter is intended for the treatment of hemodynamically significant coronary artery stenosis for the purpose of improving myocardial perfusion. A cutting/scoring PTCA catheter may also be indicated for use in complex type C lesions or for the treatment of in-stent restenosis.(2)
Classification. Class III (premarket approval). As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed. See § 870.3.